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Available online 28 January 2015Abstract Pediatric myelodysplastic syndrome (MDS) is a heterogeneous disease covering a spectrum ranging from aplasia (RCC) to
myeloproliferation (RAEB(t)). In adult-type MDS there is increasing evidence for abnormal function of the bone-marrow
microenvironment. Here, we extensively studied the mesenchymal stromal cells (MSCs) derived from children with MDS.
MSCswere expanded from the bone-marrow of 17 MDS patients (RCC: n = 10 and advancedMDS: n = 7) and pediatric controls (n = 10). No
differences were observed with respect to phenotype, differentiation capacity, immunomodulatory capacity or hematopoietic support.
mRNA expression analysis by Deep-SAGE revealed increased IL-6 expression in RCC- and RAEB(t)-MDS. RCC-MDS MSC expressed increased
levels of DKK3, a protein associated with decreased apoptosis. RAEB(t)-MDS revealed increased CRLF1 and decreased DAPK1 expressions.
This pattern has been associated with transformation in hematopoietic malignancies. Genes reported to be differentially expressed in
adult MDS-MSC did not differ between MSC of pediatric MDS and controls.
An altered mRNA expression profile, associated with cell survival and malignant transformation, of MSC derived from children with MDS
strengthens the hypothesis that themicro-environment is of importance in this disease. Our data support the understanding that pediatric
and adult MDS are two different diseases. Further evaluation of the pathways involved might reveal additional therapy targets.
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199Pediatric MDS derived mesenchymal stromal cells display normal functionality in vitroIntroduction immunomodulatory and hematopoietic assays. In addition,Pediatric myelodysplastic syndrome (MDS) represents a
range of disorders characterized by dysplastic morphology
comprising in total less than 5% of pediatric hematological
malignancies (Hasle et al., 2004). The spectrum of MDS
ranges from refractory cytopenia of childhood (RCC) to
advanced MDS with excess of blasts (RAEB) with increasing
risk of leukemic transformation (Hasle et al., 2003). Survival
has increased from 30 to 60% since hematopoietic stem
cell transplantation (HSCT) is applied (Strahm et al., 2011;
Sasaki et al., 2001; Woods et al., 2002). The pathophysiology
of MDS is not fully elucidated. However, genetic predispo-
sition, acquired cytogenetic abnormalities and abnormal
immune responses have been linked to MDS (Strahm et al.,
2011; Hasle and Niemeyer, 2011). These aspects do not
explain the entire range of disease in pediatric or adult MDS.
Recently, it has been suggested in adult MDS that impaired
interaction between hematopoietic precursor cells and their
bone-marrow microenvironment might contribute to the
disease (Zhang et al., 2012). In children, no conclusive data
is yet available.
Mesenchymal stromal cells (MSCs) have been identified
as supporting cells of hematopoietic stem cells (HSC) in vivo
and in vitro (Morikawa et al., 2009; Mendez-Ferrer et al.,
2010; Sugiyama et al., 2006) and linked to disease, as
aberrant MSC function was shown to contribute to the
pathophysiology of malignant disorders in murine models
(Raaijmakers et al., 2010; Schepers et al., 2013). Charac-
teristics of MSCs from adult MDS patients have been
extensively studied focusing on cytogenetic and molecular
abnormalities (Blau et al., 2011; Lopez-Villar et al., 2009;
Flores-Figueroa et al., 2008) as well as gene and protein
expressions (Flores-Figueroa et al., 2008; Marcondes et al.,
2008; Santamaria et al., 2012). In addition, abnormal
immunomodulation (Marcondes et al., 2008; Wang et al.,
2013; Zhao et al., 2012a) as well as decreased hematopoietic
support (Zhao et al., 2012a; Ferrer et al., 2013) by MSCs has
been reported in MDS. However, these data remain
conflicting with other studies reporting no abnormalities in
stromal function (Flores-Figueroa et al., 2008; Klaus et al.,
2010; Alvi et al., 2001). Differences in results may be
explained not only by a variety of MSC expansion protocols
and experimental set-up, but also by the heterogeneity of
the disease (Aizawa et al., 1999). Studies reporting on
(cyto)genetics and function of MDS-MSC have been summa-
rized in Supplementary Tables S1 and S2.
Pediatric MDS is a very rare disease and publications on
the role of stroma in the ontogeny and maintenance of
pediatric MDS are limited to a case report on aberrant
hematopoietic support by MSC derived from an MDS patient
with trisomy 8 (Narendran et al., 2004), a study using
stroma cells of 7 MDS patients (Borojevic et al., 2004), and a
gene-expression analysis of the stromal compartment by the
same research group (Roela et al., 2007). Nevertheless these
scarce reports suggest an aberrant support of hematopoiesis
associated with an altered gene expression profile of MSCs.
In the present study we compared MSCs derived from
children with RCC and RAEB(t)/MDS-AML to MSCs expand-
ed from age-matched healthy controls. Biological char-
acteristics, e.g., differentiation capacity and phenotype
were analyzed. MSC function in vitro was evaluated bygenome wide gene-expression profiles were studied using
Deep-SAGE sequencing.Materials and methods
Patients and MSC expansion
Children referred to our center for HSCT were included in
this study according to a protocol (P08.001) approved by the
Institutional Review Boards on Medical Ethics. Next to the
bone-marrow of 10 healthy controls (HC, median age 7.4,
range 1.1–16.4 years) being HSCT donors, bone-marrow of
17 MDS patients (10 RCC, 2 RAEB, 4 RAEBt, 1 MDR-AML) was
collected at diagnosis and prior to treatment initiation. The
WHO classification adapted for children was used for the
classification of patients. (2) MSCs from children with RAEB,
RAEBt and MDR-AML were grouped as advanced MDS to
enable the comparison between advanced and RCC-MDS. In
addition, bone-marrow after HSCT was collected from 9
children (4 RCC, 1 RAEB, 1 RAEBt, 3 MDR-AML) including 6
paired samples (Table 1).
MSCs were expanded and characterized as previously
described (Calkoen et al., 2013). Briefly, bone-marrow
mononuclear cells (MNCs) obtained after Ficoll separa-
tion were cultured in DMEM (Invitrogen, Paisley, UK)
containing 100 U/mL penicillin/100 μg/mL streptomycin
(P/S; Invitrogen) and 10% (v/v) fetal bovine serum (FBS;
VWR International, Bridgeport, NJ, USA). Non-adherent
cells were removed by refreshing the medium twice
weekly. Upon reaching confluency MSCs were harvested,
pooled and passaged for further expansion resulting in
non-clonal MSCs. Phenotype (CD73, CD90, CD105 posi-
tive; CD3, CD31, CD34, CD45, CD86, HLA-DR negative)
and differentiation capacity towards osteoblasts and adipo-
cytes were investigated at passages 2–3 and 5–7, respective-
ly. All but anti-CD105 (Ancell Corporation Bayport, MN)
antibodies were derived from Becton Dickinson Biosciences
(BD), San Diego, CA, USA. Culture supernatant was collected
after reaching 80% confluency at passages 3–5 for measure-
ment of cytokine production.Cytogenetics
To exclude common chromosome abnormalities in MSCs and
malignant cells, interphase fluorescence in situ hybridiza-
tion (FISH) for chromosomes 7 and 8 was performed on
MSCs from patients with known monosomy 7 or trisomy 8
using the following probes: Vysis LSI D7S486/CEP7 and LSI
IGH/LSI MYC, CEP8 (Abbott Laboratories, Abbott Park,
IL,USA) (Bronkhorst et al., 2011).Chimerism analysis
Chimerism (donor or recipient origin) was studied by
cytosine adenine (CA)-repeat analysis in MSCs cultured
from the bone-marrow harvested after HSCT as previously
described (Lankester et al., 2010).
Table 1 Characteristics of patients included in the study.
UPN Sex Age (yrs) at HSCT Diagnosis Donor type Donor Source Conditioning Remark
MSC
Cytogenetics in
hematopoietic cells
Pre-HSCT
MSC
Post-HSCT MSC
MSC-MDS001 M 8.9 RAEBt MUD BM Bu, Cy, Mel, rATG – Yes Yes + 7 months
MSC-MDS002 F 13.3 RAEB MUD PBSC Bu, Cy, Mel, rATG Trisomy 1, monosomy 7,
trisomy 8
Yes Yes + 4 months
MSC-MDS003 F 5.4 RCC IRD BM Bu, Cy, Mel Only post Monosomy 7 Yes + 2 months
MSC-MDS005 M 6.1 RCC ORD PBSC/MSC 1st: Flu, Thio, rATG,
2nd: Treo, Flu, Campath
– Yes Yes + 2 months
MSC-MDS008 F 14.2 MDR-AML IRD BM Bu, Cy, Mel Only post – Yes + 2 months
MSC-MDS009 F 15.8 MDR-AML ORD PBSC/MSC Thio, Treo Flu, rATG Only post Yes + 7 months
MSC-MDS011 F 10.2 RCC MUD BM Flu Thio Campath – Yes Yes + 3 months
MSC-MDS015 F 9.3 RCC MUD BM Bu, Flu, rATG Monosomy 7 Yes Yes + 2 months
MSC-MDS017 M 14.0 RCC MUD BM Bu, Cy, Mel, rATG – Yes
MSC-MDS018 M 14.6 RAEBt MUD BM Bu, Cy, Mel, rATG – Yes
MSC-MDS019 F 4.8 RCC MUD BM Bu, Cy, Mel, Campath Monosomy 7 Yes
MSC-MDS020 M 13.3 RAEB MUD BM Bu, Cy, Mel, Campath Monosomy 7 Yes
MSC-MDS021 M 13.3 RAEBt IRD BM Bu, Cy, Mel, rATG Trisomy 8 Yes
MSC-MDS022 F 4.1 RCC MUD CB Bu, Cy, Mel, rATG Monosomy 7 Yes
MSC-MDS023 F 1.2 RAEBt MUD BM Bu, Mel, ARA-C, rATG Monosomy 7 Yes
MSC-MDS024 M 4.1 MDR-AML IRD BM 1st: Flu Thio Campath, 2nd:
Flu Thio treo rATG, 3rd none
– Yes Yes + 3 months
MSC-MDS026 M 17.8 RCC MUD BM Flu, Thio, Campath – Yes
MSC-MDS027 M RCC n.a. No HSCT – Yes
MSC-MDS028 F RCC n.a. No HSCT – Yes
MSC-MDS029 F 17.6 RCC MUD BM Flu, Thio, Campath – Yes
RCC: refractory cytopenia of childhood; RAEB: refractory anemia with excess of blasts; RAEBt: RAEB in transformation; MDR-AML: myelodysplasia related acute myeloid leukemia; HSCT:
hematopoietic stem cell transplantation; MUD: matched unrelated donor; IRD: identical related donor; ORD: other related donor; BM: bone marrow; PBSC: peripheral blood stem cells; MSCs:
mesenchymal stromal cells; CB: cord blood; Bu: busulphan; Cy: cyclofosfamide; Mel: melphalan; rATG: rabbit anti-thymocyte globulin; Flu: fludarabine; Thio: thiotepa; Treo: treosulphan;
ARA-C: cytosine arabinoside; n.a.: not applicable.
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201Pediatric MDS derived mesenchymal stromal cells display normal functionality in vitroImmunomodulatory assays
The effect of MSCs (30 Gy irradiated) on proliferation of
peripheral blood (PB) MNCs obtained from adult blood bank
donors (100,000 cells/well) after stimulation with phytohe-
magglutinin (PHA 2 μg/mL) was analyzed at MSC:PBMC ratios
of 1:5 and 1:40. MSCs and PB-MNCs were co-cultured in RPMI
P/S, 10% (v/v) fetal calf serum (FCS) for 5 days with the
addition of 3H-thymidine (1 μCi/well; Perkin Elmer, Welles-
ley, MA, USA) for the last 16 h to measure proliferation using
a β-counter (Perkin Elmer). Experiments were performed in
triplicate.
To evaluate the effect of MSCs on antigen presenting
cells, monocytes were isolated from PB using positive
CD14 selection (Miltenyi, Bergisch Gladbach, Germany) and
cultured with IL-4 (40 ng/mL) and GM-CSF (800 IU/mL) (both
from Tebu-Bio, Le Perray en Yvelines, France) for 5 days to
differentiate towards immature dendritic cells (DCs). Cells
were harvested or cultured for 2 additional days with IL-4,
GM-CSF, IFN-γ (500 U/mL, Boehringer, Mannheim, Germany)
and CD40-ligand (0.25 μg/mL Beckman-Coulter, Marseille,
France) to generate mature DCs. Cells were phenotyped by
flow cytometry for the expression of CD14 and CD1a (BD) on
day 0, day 5 and day 7 after co-culturing of monocytes and
MSCs at MSC:monocyte ratios of 1:5, 1:40 or 1:100 or after
culturing monocytes without MSCs.Hematopoietic support
Short-term co-culture assays with MSCs and hematopoietic
progenitor cells (HPCs) were performed to determine the
supportive capacity of MSCs for HPC maintenance and
differentiation. Therefore, HPCs were isolated from the
remaining material of G-CSF mobilized stem cell grafts from
healthy transplant donors using CD34 positive selection
(Miltenyi). Selected cells expressed N90% CD34 after
purification. Short-term cultures of 500 CD34 selected
cells/well without or with MSCs (CD34:MSC ratios of 1:2
and 1:20) were performed in Stemspan medium (H3000,
StemCell Technologies, Vancouver, Canada) with addition of 1%
P/S, stem cell factor (SCF, 100 ng/mL, StemCell Technologies)
and Flt3-ligand (Flt3-L, 100 ng/mL, StemCell Technologies),
because SCF and Flt3-L are not produced by MSCs. Cultures
were initiated with 10 × 103 CD34+ cells at a CD34:MSC ratio
of 1:5 for flow cytometry analysis. Half of the culture
medium was refreshed with the addition of growth factors
on days 4, 7 and 11. Proliferation (day 7) and differentiation
(days 7 and 14) were assessed using 3H-thymidine during the
last 16 h or flow cytometry, respectively. Antibodies used
for flow cytometry were anti-CD34-PE, anti-CD45-FITC,
anti-CD38-Percpc5.5, anti-CD45-Percpc5.5, anti-CD14-FITC,
anti-CD33-APC, anti-GPA-PE (glycophorin A) and anti-CD13-PE
(all antibodies from BD).
In long-term cultures, CD34 selected cells (50,000 cells)
were cultured on a confluent MSC layer for 3–5 weeks in the
absence of growth factors. Cells were harvested and
counted using trypan blue as viability stain.
To determine the functional impact of HPC expansion
and differentiation after short-term culture, non-adherent
cells were harvested after 7 days of culturing CD34+ cells
in the absence or presence of MSCs (CD34:MSC ratio of 1:5),transferred (1000 cells/dish) to methylcellulose containing
essential growth factors, i.e., SCF, GM-CSF, IL-3, and
erythropoietin (EPO) (H4434 StemCell Technologies), and
cultured for 14 days (colony-forming unit assay; CFU-assay).
Colonies were scored by two independent observers accord-
ing to standard guidelines for the definition of CFU-GEMM,
BFU-e, CFU-GM, CFU-G and CFU-M. Results are depicted as
the average of duplicate wells. To determine a more direct
effect of MSCs on HPCs in CFU-assays, MSCs (30,000 or
150,000 per dish) were added to freshly purified HPCs (500
cells/dish) in methylcellulose containing SCF, GM-CSF, IL-3
and EPO (H4434 StemCell Technologies). The direct effect of
MSCs on colony formation was also assessed in methylcellu-
lose containing EPO (H4330 StemCell Technologies) only.
Cells were harvested and phenotyped after scoring of
colonies in the CFU-assay.Cytokine expression
IL-6 quantification in MSC culture supernatants was per-
formed by ELISA (Sanquin, Amsterdam, the Netherlands)
according to the manufacturer's instructions.Gene expression
Total RNA was isolated at passages 2–3 using a Qiagen
RNeasy Minikit (Qiagen, Hilden, Germany). mRNA was
profiled using Deep-SAGE sequencing using Illumina technol-
ogy (Mastrokolias et al., 2012). CATG was added to the 5′
end of the 17 base pair sequences obtained. Data were
mapped against the UCSC hg19 reference genome using
Bowtie for Illumina (version 1.1.2) without the permission of
one mismatch and suppression of reads if more than one best
match existed. Tags aligned to the same gene were summed
for further analysis. Gene information was added to the
sequences with the biomaRt package in R (version 2.16.0).
The expression data will be published online in the Gene
Expression Omnibus (GEO).
Expression of genes of interest was validated using
independent biological samples by RT-PCR after generation
of cDNA (cDNA synthesis kit, Roche, Basel, Switzerland)
using the listed primers (Table S3), as previously described
(Mastrokolias et al., 2012). Expression levels were calculat-
ed relative to expression of the housekeeping genes GAPDH
and HPRT1.Statistical analysis
Graphpad 6 (Prism, La Jolla, CA) was used for data-analysis.
Mann–Whitney and Wilcoxon matched-pairs signed rank
tests were performed to compare different groups. Differ-
ential gene expression analysis was performed in R (version
2.15.0), using the EdgeR (version 3.2.4) and Limma (version
3.16.7) data analysis packages (Robinson et al., 2010; Anon.,
2012; Smyth et al., 2005). Correction for multiple test-
ing was performed according to Hochberg and Benjamini
(1990). Adjusted p-values b 0.05 were considered statisti-
cally significant.
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Expansion and characterization of MSC
MSCs were successfully cultured from the bone-marrow of all
patients and controls. Expanded MSCs expressed CD73, CD90
and CD105, whereas the cells did not express lineageFigure 1 Immunomodulation by MDS-MSC. A. Both healthy control
RCC n = 2) significantly suppressed PHA-induced PBMC (n = 4 health
significant differences were observed between MDS patients (black
MSCs suppressed the differentiation of monocytes (CD14+ cells) tow
(hatched boxes: no MSC added). No significant differences were ob
Boxes represent median and 25–75 percentiles and the whiskers the
Wilcoxon matched-pairs signed rank tests (in A for comparison o
comparison between HC and MDS). n.s.: not significant.markers (Supplementary Fig. S1A). MSCs differentiated
towards adipocytes and osteoblasts when cultured in culture
media supporting these distinct directions of differentiation
(Figs. S1B–E). In one de novo RCC patient (UPN: MDS026) no
osteoblast differentiation was established. Post-HSCT de-
rived MSCs were of complete patient origin in all children
that were analyzed (n = 6). Monosomy 7 was not detected in(HC, n = 6) and MDS-MSCs (n = 5 of which RAEB/RAEBt n = 3 and
y adults) proliferation at MSC:PBMC ratios of 1:40 and 1:5. No
circles) and controls (white circles). wo MSC: without MSC. B–E.
ards dendritic cells (CD1a+ cells) in a dose-dependent manner
served between HC (white boxes) and MDS-MSC (black boxes).
minimum and maximum values. p-Values were calculated using
f different MSC ratios) and Mann–Whitney tests (in A–E for
203Pediatric MDS derived mesenchymal stromal cells display normal functionality in vitroMSCs from any bone marrow harvested prior to HSCT from
children with monosomy 7 (n = 6). The MSC lines generated
from the two patients with trisomy 8 in the hematopoietic
cell compartment tested negatively for trisomy 8.
Immunomodulation
MSCs down modulate functions of various cell types involved
in innate and adaptive immunity (Le Blanc and Mougiakakos,
2012). The effect of MSCs of pediatric MDS patients and
healthy children on T-cell proliferation and monocyte
differentiation was investigated. MSCs suppressed the
PHA-induced PB MNC proliferation in a dose-dependent
manner. No differences in suppressive capacity were
observed between MDS-MSCs and healthy control (HC-)MSCs
(Fig. 1A).
To investigate the suppressive effect of MSCs on DC
maturation, MSC-monocyte co-cultures were performed.
The purified monocyte fraction was N95% CD14+ and b1%Figure 2 MDS-MSCs support maintenance and differentiation of he
HSCT donors were cultured in the absence (wo MSC) or presence of MS
or healthy controls (HC) in the presence of SCF and Flt3-L. Proliferat
B–C. CD34+ expression declined overtime, but MSCs supported the e
cells were retained in comparison with cultures in the absence of MS
starting with 10 × 103 HPCs. Flow cytometry data presented in C are
CD45 expression and the percentage of CD34+ cells within the CD
decreased significantly in the absence of MSCs, the absolute number
1:5). Data depicted in A, B and D represent at least 2 independent ex
MSCs, white bars: healthy control (HC)-MSCs, black bars: MDS-MSCs
methylcellulose to test their capability of colony formation. Graphs r
CFU-assay resulting from the investigation of 4 MDS-MSCs and 3 HC-M
without MSCs. Bars depict the mean with standard deviation. p
significant.CD1a+ at the start of MSC-monocyte co-culture. After 5 days
of culture with GM-CSF and IL-4, the monocytes lost CD14
expression and gained CD1a, characteristic for DCs. This
process further progressed from day 5 to 7 during maturation
of DCs in the presence of GM-CSF, IL-4, IFN-γ and
CD40-ligand. MSCs of controls and MDS patients showed
inhibition of the differentiation at days 5 and 7 at various
MSC:monocyte ratios (Figs. 1B–E). No differences between
both groups were observed. RAEB(t)-MSCs and RCC-MSCs
showed comparable suppressive effects in both assays (data
not shown).Expansion of hematopoietic progenitor cells
As part of the stromal bone-marrow compartment, MSCs play
an important role in the regulation of hematopoiesis through
interaction with HPCs (Mendez-Ferrer et al., 2010). The
effect of MSCs of pediatric MDS patients and healthy childrenmatopoietic progenitor cells (HPCs). A. CD34+ cells (500 cells) of
Cs (CD34:MSC of ratios 1:2 and 1:20) obtained from MDS patients
ion of HPCs at day 7 was assessed by 3H-thymidine incorporation.
xpansion of HPCs (CD34+ cells) and a higher percentage of CD34+
Cs. Results shown are from cultures at a CD34+:MSC ratio of 1:5
obtained after 14 days of culture and show plots of CD34 versus
45+ cell population. D. Whereas the absolute number of HPCs
of HPCs increased in co-cultures with MSCs (CD34+:MSC ratio of
periments of 5 HC-MSCs and 8 MDS-MSCs (gray bars: without (wo)
). E. Non-adherent cells harvested at day 7 were transferred to
epresent the total number of CFU and indicated CFU types in the
SCs present during the initial HPC and MSC co-culture. wo MSC:
-Values were calculated using Mann–Whitney tests. n.s.: not
204 F.G.J. Calkoen et al.on expansion and differentiation of CD34+ HPCs was
investigated in various in vitro culture systems.
HPC (CD34+ cells) proliferation was enhanced in the
presence of MSCs in a dose-dependent manner after
stimulation with SCF and Flt3-L for 7 days (Fig. 2A). The
percentage of cells expressing CD34 declined over time, but
the level of this decline is significantly less in cultures
containing MSCs (Figs. 2B–C). In co-cultures of HPCs with
MSCs, CD38 expression, associated not only with activation
but also with loss of stemcellness (Calloni et al., 2013;
Chillemi et al., 2013), was significantly increased at day 14
on both CD34+ and CD34− cells (CD34+ cells, mean and SD:
without MSCs: 18.8 ± 1.5%; plus HC-MSCs: 46.8 ± 8.9%;
plus MDS-MSCs: 52.0 ± 5.0%. CD34− cells: without MSCs
25.9 ± 2.9%; plus HC-MSCs: 54.9 ± 9.4%; plus MDS-MSCs:
61.5 ± 5.3%). In cultures with MDS-MSCs, differentiation towards
myeloid-lineage cells was not enhanced in comparison with
cultures with HC-MSCs or without MSCs (CD14+ cells as a
percentage of CD45+ cells, mean and SD: without MSC: 16.2 ±
2.0%; plus HC-MSCs 16.0 ± 2.5%; plus MDS-MSCs: 19.0 ± 2.2%).
The absolute number of CD34+ cells decreased signifi-
cantly when HPCs were cultured in the absence of MSCs. In
contrast, in the presence of MSCs, the HPC (CD34+)
population expanded from day 0 to day 7. From day 7 to
day 14 the CD34+ numbers remained unchanged compared to
day 7 (Fig. 2D).
Non-adherent cells (1000 cells), harvested from HPC
cultures with or without MSCs at day 7, were transferred to
methylcellulose for CFU-C analysis. Cells that have previ-
ously been co-cultured with MSCs gave rise to higher
numbers of CFU-C, compared to HSCs that have been
cultured in the absence of MSCs (Fig. 2E). This is in
accordance with the increased CD34+ numbers that were
observed (Fig. 2D). No differences were found in the types of
colonies that were formed and this was independent of the
presence or absence of MSCs. Overall, the impact of MSCs in
these various assays of HPC function was similar for MDS
patients and healthy controls, as well as for RAEB(t) versus
RCC patients (data not shown).Maintenance of hematopoietic progenitor cells
To exclude the influence of exogenous growth factors on
HPC expansion and the capacity to mount colonies, 50 × 103
CD34+ cells were seeded on confluent MSC layers and
cultured for 3–5 weeks without the addition of growth
factors. When cultured in the absence of MSCs, all CD34+Figure 3 MSCs of MDS patients support colony formation in CFU-ass
healthy controls (HC-MSC), of MDS patients (MDS-MSC) or no MSCs (
cells) of HSCT donors at initiation of colony forming unit assays (CFU
Addition of MSCs supports the increase of the number of colonies (MD
the number of colonies in cultures without MSCs (range: 83–105) was
at day 14 after culture initiation. The percentage (B) and number (C
of MSCs, irrespectively whether MSCs were derived from MDS patient
healthy controls (HC; n = 3), co-cultured with HPCs in the presence
and CFU-M, but not of the other colony types (read-out CFU-assay
standard deviation. p-Values were calculated using Mann–Whitney
(wo) MSCs. n.s.: not significant.cells died. In contrast, the CD34+ cells were maintained
when cultured in the presence of MSCs. The number of viable
cells harvested following 3–5 weeks of culture did not differ
between MDS-MSCs (n = 4) and HC-MSCs (n = 2) (Fig. S2A).
Non-adherent cells harvested after 3 weeks of culture in the
presence of HC-MSCs or MDS-MSCs formed similar numbers of
colonies in CFU-assays (range 12–27 vs 8–32, respectively)
(Fig. S2B).
Support of colony formation
To study the direct influence of MSCs on colony formation by
freshly isolated HPCs, MSCs (30 × 103 or 150 × 103 cells/well)
were added to purified HPC (500 cells/well) inmethylcellulose
containing growth factors, i.e., SCF, GM-CSF, IL-3, and EPO.
The total number of colonies at day 14 was increased by the
addition of MSCs (p = 0.01). A significant increase was seen
in CFU-GEMM, CFU-GM and CFU-M (Fig. 3A). The proportion
of CFU-GM colonies was increased when cells were cultured
in the presence of MSCs compared to CFU-C assays in the
absence of MSCs. In accordance with this, the percentage
of CD45+GPA− myeloid cells were increased in the
non-adherent cell population (colonies) harvested at day
14 from cultures containing MSCs (Figs. 3B–C). No differ-
ences in the supportive effect on colony formation and HPC
differentiation were observed between MDS-MSCs (n = 6)
and HC-MSCs (n = 4). When HPCs were cultured in the
presence of HC-MSCs (n = 3) or MDS-MSCs (n = 3) in
methylcellulose with erythropoietin and without GM-CSF,
SCF and IL-3 the number and size of colonies were
significantly increased in comparison with cultures without
MSCs (Fig. 3D). In conclusion, HC-MSCs and MDS-MSCs have
similar effects on colony formation in vitro.
Gene and protein expressions
In functional assays no evidence was obtained for a disturbed
MSC function in children with MDS. However, these func-
tional studies are limited and the results do not formally
exclude the possible existence of biologically relevant
differences between MDS-MSC and HC-MSCs. To further
investigate this Deep-SAGE was performed on total RNA
identifying the expression of all mRNA from the 3′-end.
MSCs derived from RCC (n = 4), RAEB(t) (n = 4) and
healthy controls (HC, n = 8) were analyzed. A median of
15.9 × 106 reads (range 9.5 × 106–30.6 × 106) was obtained.
Between 59.3% and 68.4% (median 65.6%) of reads wereays. A–C. MSCs (30,000 cells, or 150,000 cells when indicated) of
wo MSC) were added to freshly isolated HPCs (CD34+ cells, 500
-assay). Cultures contain exogenous SCF, GM-CSF, IL-3 and EPO.
S n = 6, HC n = 4). To compare data from different experiments,
set at 100. Colonies were scored and harvested for phenotyping
) of CD45+GPA− cells are increased in CFU-assays in the presence
s or healthy controls (HC). D. MSCs from MDS patients (n = 3) and
of EPO only, significantly increase the formation of CFU-GEMM
at day 14). wo MSC: without MSCs. Bars represent mean and
tests. *: statistically different (p b 0.05) from culture without
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Figure 4 Heat map depicting clustering of MDS derived MSCs. Gene expression was analyzed using LIMMA software. MSCs of
different groups (RAEB(t)-MDS, RCC-MDS and healthy controls (HC)) showed hierarchical clustering in a heat map of differentially
expressed genes. Color intensity of the squares correlates with increased gene expression.
206 F.G.J. Calkoen et al.aligned to the genome using Bowtie; with a median of 55.4%
(min 45.3%; max 57.6%) of the reads being mapped to an
exon.
A heat map reflecting the top 50 differentially expressed
genes demonstrates clustering of healthy control, RCC and
RAEB MSC (Fig. 4). The gene expression profile of RCC
clustered more towards healthy controls than RAEB(t). After
correction for multiple testing, IL6 and dickkopf 3 homologue
(DKK3) were significantly expressed higher in RCC-MSCs
compared to HC-MSCs (p = 0.002 and p = 0.005, respectively).
Death-associated protein kinase 1 (DAPK1) expression was
decreased (p = 0.049) in RAEB(t)-MSCs compared to HC-MSCs,
whereas cytokine receptor-like factor 1 (CRLF1) and IL6
expressions were increased (p = 0.009 and p = 0.048,respectively). Differential expression of IL6, DKK3, DAPK1
and CRLF1was confirmed by RT-PCR (Fig. 5A). In addition, the
IL-6 concentration in culture supernatants of MSCs from the
bone-marrow obtained at diagnosis was significantly increased
in all MDS cases (n = 10) compared to supernatants of healthy
control MSCs (n = 8) (p b 0.001; Fig. 5B).
Deep-SAGE and RT-PCR showed that IL-6 expression was
elevated in MSCs of both RCC and RAEB(t) obtained prior to
HSCT. Of note, after HSCT, IL6 and DAPK1 expression levels
in MSCs were comparable to HC-MSCs (Fig. 5C). IL-6
concentration in MDS-MSCs culture supernatant was, al-
though lower than in MSC samples generated from the
bone-marrow taken pre-HSCT, still significantly higher than
in supernatant of HC-MSCs (Fig. 5B). DKK3 and CRLF1
Figure 5 Differential mRNA expression by MSCs of MDS patients. A: Aberrant gene expression detected by Deep-SAGE was
confirmed by RT-PCR. IL-6 expression was increased in MSCs of both RCC and RAEB(t) MDS patients at diagnosis compared to MSCs of
healthy controls (HC). In contrast, DKK3 was specifically increased in RCC-MDS, whereas CRLF1 and DAPK1 were significantly altered
in RAEB(t)-MDS derived MSCs. Data were normalized using GAPDH and HPRT1 as house-keeping genes (HC-MSC n = 10, RCC-MSC n = 7
and RAEB(t)-MSC n = 4). B: Increased IL-6 gene expression in MSCs of MDS patients pre-HSCT (n = 10) compared to HC-MSCs (n = 8)
was confirmed by ELISA quantifying IL-6 secreted by MSCs in culture supernatant. IL-6 concentration was still elevated in supernatant
of MSCs generated from the bone-marrow obtained after HSCT, although there is a trend to normalization (n = 7). C: Gene expression
analysis demonstrated a normalized mRNA expression in MDS-MSCs after HSCT compared to HC-MSCs for IL-6 and DAPK1. RCC:
refractory cytopenia; RAEB(t): refractory anemia with excess of blasts (in transformation); HC: healthy control; DKK3: dickkopf 3
homologue; CRLF1: cytokine receptor-like factor 1; DAPK1: death-associated protein kinase 1; HSCT: hematopoietic stem cell
transplantation; boxes represent median and 25–75 percentiles with whiskers marking the range; Mann–Whitney statistical tests
were performed to compare the different groups; *: p b 0.05; **: p b 0.01; ***: p b 0.001. n.s.: not significant.
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RAEB(t) patients, respectively, were not significantly al-
tered compared to MDS-MSCs before HSCT or to HC-MSCs
(data not shown).
Potential candidate genes based on their reported
differential expression in adult MDS-MSCs, i.e., AURKA,
AURKB, SCF, G-CSF and GM-CSF (Santamaria et al., 2012;
Ferrer et al., 2013; Zhao et al., 2012b; Oliveira et al., 2013),
were specifically analyzed and no differences were observed
comparing RCC-MSCs, RAEB(t)-MSCs and HC-MSCs.
Similarly, a comparable expression level of CXCL12,
Dicer1 and Drosha in pediatric MDS-MSCs versus HC-MSCs
was confirmed by RT-PCR (data not shown).Discussion
The spectrum of pediatric MDS ranges from aplasia to
myeloproliferative disease. The pathophysiology of the
disease has been attributed to different cytogenetic abnor-
malities (Gohring et al., 2010). Previous studies in mice and
in human adults have linked the interaction of hematopoi-
etic progenitors and the micro-environment to the progres-
sion of disease in several hematopoietic disorders (Zhang et
al., 2012; Schepers et al., 2013). In adult MDS specific
alterations in the MSCs have been reported as summarized in
Table S1. Data on pediatric MDS are limited (Table S2). In
this study, we compared the MSC characteristics and
208 F.G.J. Calkoen et al.function in children with different types of MDS with
healthy controls. Differences were neither observed with
respect to the differentiation capacity of MSCs, their
immunomodulatory capacity using T-cell proliferation and
monocyte differentiation to dendritic cells as read-out,
nor regarding their impact on maintenance and differen-
tiation of hematopoietic progenitor cells. In addition, cell
viability in co-cultures was equally increased by both
groups of MSCs, as assessed by trypan-blue staining (data
not shown).
However, evaluation of total mRNA expression profiles
demonstrated gene expression differences between MSCs
derived from pediatric MDS patients and controls. Cytoge-
netic abnormalities present in the hematopoietic cells could
not be detected in the stromal compartment, and, there-
fore, this cannot explain the differential gene expression.
The partial normalization of IL6 and DAPK1 expressions
in MSCs after HSCT in these patients demonstrates that
the expression differences can be reversed. Of note, using
chimerism analysis, the presence of donor MSCs in the
expanded cells has been excluded.
Differential gene expression between pediatric MDS in
general and healthy controls was most prominent for IL6.
This gene has previously been reported to be over-expressed
in adult MDS and in one child with MDS and a constitutional
trisomy 8 (Zhao et al., 2012a; Narendran et al., 2004). In
contrast, other studies in adults did not show differential
IL6 expression between MDS patients and healthy controls
(Flores-Figueroa et al., 2002, 2008; Zhao et al., 2012a; Klaus
et al., 2010). IL6 has been described to increase myeloid
differentiation via STAT3 activation and support multiple
myeloma cell growth and survival (Minami et al., 1996;
Zhang et al., 2010; Csaszar et al., 2013; Gunn et al., 2006).
STAT3 up-regulation was not observed in this pediatric MDS
cohort. In addition, IL-6 is one of the cytokines responsible
for bone-remodeling in inflammatory and malignant diseases
(Ara and Declerck, 2010; Dayer and Choy, 2010). Suppression
of monocyte to dendritic cell differentiation is dependent on
IL-6 (Melief et al., 2013). However, we did not observe a
correlation between the degree of the suppressive effect of
MSCs and the level of IL-6 expression, suggesting that IL-6 is
not the sole factor hampering this differentiation.
Besides IL6 (RCC- and RAEB(t)-MDS), DKK3 (RCC-MDS), CRLF1
and DAPK1 (RAEB(t)-MDS) were differentially expressed byMSCs
of healthy controls versus MDS. DKK3 and CRLF1 have been
associated with increased cell survival by suppressing apoptosis
in MSCs and neuroblastoma cells, respectively (Song et al.,
2006; Looyenga et al., 2013). Differential expression of these
genes did not correlate with MSC expansion rates (data not
shown). In addition, increased CRLF1 in combination with IL-6
has been described in idiopathic pulmonary fibrosis causing
inflammation, but suppression of fibrosis (Kass et al., 2012).
DAPK1 down-regulation, associated with malignant transforma-
tion, has been described in the hematopoietic cells in adult
RAEB(t)-MDS potentially attributing to aberrant methylation
(Raval et al., 2007; Qian et al., 2010; Wu et al., 2011; Claus et
al., 2012; Karlic et al., 2013). We demonstrate a similar
expression profile in our MSCs, with expression in RCC-MDS
being similar to HC-MSCs, and down-regulation in RAEB(t)-MSCs.
After successful HSCT, DAPK1 expression was normalized. The
allogeneic HSCT procedure leading to elimination of derailed
cells and restoration of hematopoiesis through donor HPCsmight contribute to normalization of the stromal environment
in the hematopoietic niche, including MSCs of recipient origin.
Analysis of total mRNA expression profiles not only
revealed differences between RCC and RAEB(t)/MDR-AML in
children, but also enabled us to specifically focus on genes
previously reported to be differentially expressed in adult
MDS. Genes of interest included micro-RNAs reported by
Santamaria et al. (2012) as well as genes encoding cytokines,
their receptors, chemokines and adhesion molecules. In
contrast to what has been described for adult MDS, AURKA,
AURKB, SCF, G-CSF, GM-CSF, CXCL12, Dicer1 and Drosha
were not differentially expressed in our cohort of pediatric
MDS patients compared to healthy controls. Lack of
differences in expression levels of Dicer1, Drosha and
CXCL12 was further confirmed by RT-PCR (data not shown).
This supports the current understanding that pediatric and
adult MDS are two different diseases as previous studies have
highlighted the differences between adult and pediatric MDS,
e.g., in response to treatment and rarity and prognostic value
of (epi-)genetic mutations in the hematopoietic compartment
(Hasle et al., 2004; Glaubach et al., 2014; Hirabayashi et al.,
2012). Besides IL-6, genes included in the clustered analysis
did not encode for molecules known to be involved in MSC
signaling as reviewed by Le Blanc and Mougiakakos (2012).
Our MDS cohort is heterogeneous containing RCC as well as
advanced MDS patients. Bone-marrow post HSCT was not
available in all cases, because informed consent was limited
to bone-marrow sampling on clinical indication namely relapse
risk and non-engraftment. Correlation of mRNA expression in
MSCs obtained at diagnosis with MSCs at MDS relapse after HSCT
was not feasible due to low sample numbers in combination
with limited numbers of relapse after HSCT.
Our findings demonstrate differences in mRNA expression
between pediatric MDS and age-matched healthy control
derived MSCs. This is in accordance with published data on
MSCs derived from adults with MDS, however, as expected,
not all abnormalities described in adults were present in
pediatric MDS. In addition, different expression levels of
specific genes were not associated with functional aberra-
tions in assays pointing to immunomodulation and hemato-
poiesis, potentially caused by compensatory mechanisms or
insufficient sensitivity of our tests. Growth differences be-
tween MSC precursors and use of non-clonal MSC populations
may lead to loss of information and, thereby, to potential loss
of differences between pediatric MDS and healthy control
derived MSCs. Unfortunately, data on the interaction of MSCs
with MDS patient derived hematopoietic stem cells was limited
by the available material. However, preliminary data do not
reveal differences in co-cultures of MDS-RAEB HPCs with MDS
patient or healthy control derived MSCs.
Studying the pathogenesis of MDS has been complicated by
the poor engraftment of human MDS HPCs in immunodeficient
mice (Thanopoulou et al., 2004). However, co-transplantation
of stromal cells and intramedullary transplantation of
hematopoietic cells have led to increased engraftment
(Kerbauy et al., 2004). Knockout models resulting in an
MDS-like phenotype or the of use of scaffolds with patient-
derived MSC to resemble the human bone-marrow microenvi-
ronment might be instrumental in further exploring the
potentially functional implications of these differences in
future studies (Raaijmakers et al., 2010; Groen et al., 2012;
Walkley et al., 2007).
209Pediatric MDS derived mesenchymal stromal cells display normal functionality in vitroIn conclusion, our data show that the gene expression
profile is different in MSC of children with MDS. It remains to
be elucidated whether the abnormalities are a cause or a
consequence of the disease. Normalization of the aberrant
gene expression seen in patients derived MSC after alloge-
neic HSCT is an argument favoring the latter possibility.
Induced abnormalities in the MSC by dysplastic cells might
be targets to sustain response to therapy.
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